project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9LB; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.98; rna integrity number: 7.0; age at index: 72; days to birth: -26447; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 26447; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 583.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 629; initial weight: 380.0; sample id: ceec8847-7c94-47d4-aaf2-357b4fd20df3; sample submitter id: TCGA-ZG-A9LB-01A; portion id: c4681060-77a6-4f7b-b0ca-b19b98dab7f6; portion submitter id: TCGA-ZG-A9LB-01A-11; slide id: 56576c68-7c1d-428a-991f-879433c63291; slide submitter id: TCGA-ZG-A9LB-01A-01-TSA; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 2.0; percent stromal cells: 18.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;